IF 5.4 2区医学

Infection Pub Date : 2025-04-02 DOI: 10.1007/s15010-025-02522-y

Anja Berger, Aleksandra A Zasada, Alexandra Dangel, Katarzyna Piekarska, Iwona Paradowska-Stankiewicz, Katja Bengs, Christine Noll, Andreas Sing

引用次数: 0

Kerion of the pubis.

IF 5.4 2区医学

Infection Pub Date : 2025-04-01 DOI: 10.1007/s15010-025-02518-8

Elisabeth Gomez-Moyano, Fatima Moreno-Suarez, Leandro Martinez-Pilar

引用次数: 0

Clinical and microbiologic outcomes of Stenotrophomonas maltophilia bloodstream infections.

IF 5.4 2区医学

Infection Pub Date : 2025-03-27 DOI: 10.1007/s15010-025-02512-0

Sunish Shah, Brianne Slaven, Lloyd G Clarke, Justin Ludwig, Ryan K Shields

{"title":"Clinical and microbiologic outcomes of Stenotrophomonas maltophilia bloodstream infections.","authors":"Sunish Shah, Brianne Slaven, Lloyd G Clarke, Justin Ludwig, Ryan K Shields","doi":"10.1007/s15010-025-02512-0","DOIUrl":"https://doi.org/10.1007/s15010-025-02512-0","url":null,"abstract":"Purpose: The optimal treatment for infections due to Stenotrophomonas maltophilia has not been defined.Methods: This was a multicenter, retrospective study of patients with S. maltophilia bacteremia between March 2010 to December 2023. Patients > 18 years with a positive blood culture growing S. maltophilia were included. Patients treated < 48 h or those with central line colonization were excluded. Clinical failure was defined as emergence of resistance during treatment, recurrent S. maltophilia bacteremia or death within 30 days. Outcomes for those treated with fluoroquinolone or trimethoprim-sulfamethoxazole monotherapy were compared using a propensity scored-adjusted full matching approach.Results: 217 patients were included; 17% (37/217) patients had a history of transplant. The clinical failure rate was 16% (35/217); reasons for failure included death (n = 22), recurrent bacteremia (n = 12) or treatment-emergent resistance (n = 3). One patient each with recurrence and resistance also died within 30 days. Within 90 days, resistance developed in 15 patients. The most common treatment regimens were fluoroquinolones (n = 103) and trimethoprim-sulfamethoxazole (n = 45) as monotherapy. Use of high-dose trimethoprim-sulfamethoxazole did not improve clinical success rates. Combination therapy was employed in 10% (21/217) of patients. After applying full-matching criteria, there was no difference in rates of 30-day clinical failure (aOR = 1.02; 95% CI 0.25-3.82; P = 0.999) or mortality (aOR = 1.4; 95% CI 0.25-7.25; P = 0.727) among patients treated with fluroquinolone or trimethoprim-sulfamethoxazole monotherapy.Conclusion: Monotherapy with fluoroquinolones or trimethoprim-sulfamethoxazole were used most commonly to treat S. maltophilia bacteremia across centers. Patient outcomes did not differ between treatment regimens and the overall rate of treatment-emergent resistance was low.","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: A simple scoring algorithm predicting paravertebral and/or Iliopsoas abscess among adults with community-onset bloodstream infections: matters of PVL-producing staphylococcus aureus.

IF 5.4 2区医学

Infection Pub Date : 2025-03-25 DOI: 10.1007/s15010-025-02510-2

Ching-Chi Lee, Ching-Yu Ho, Ming-Yuan Hong, Yuan-Pin Hung, Wen-Chien Ko

引用次数: 0

Corynebacterium rouxii in a free-roaming red fox: case report and historical review on diphtheria in animals.

IF 5.4 2区医学

Infection Pub Date : 2025-03-25 DOI: 10.1007/s15010-025-02515-x

Andreas Sing, Alexandra Dangel, Regina Konrad, Dominik M Meinel, Ingo Schwabe, Reinhard Sting, Jörg Rau, Anja Berger

引用次数: 0

Periorbital primary cutaneous mucormycosis: a case report and literature review.

IF 5.4 2区医学

Infection Pub Date : 2025-03-25 DOI: 10.1007/s15010-024-02464-x

Yan Xu, Chunyou Wang, Lian Zhang, Zhifang Zhai, Huan Wang

引用次数: 0

Trichomonas vaginalis in neonates.

IF 5.4 2区医学

Infection Pub Date : 2025-03-25 DOI: 10.1007/s15010-025-02508-w

Herbert Hof, K A Bode, H Weisser

{"title":"Trichomonas vaginalis in neonates.","authors":"Herbert Hof, K A Bode, H Weisser","doi":"10.1007/s15010-025-02508-w","DOIUrl":"https://doi.org/10.1007/s15010-025-02508-w","url":null,"abstract":"Background: Trichomonas vaginalis is one of the most prevalent pathogens responsible for non-viral sexually transmitted infections. The infection mainly affects women of childbearing age, with the potential for complications during and after pregnancy. Although perinatal transmission is rare, it carries the risk of resulting in neonatal infections. To date, only a dozen documented cases have been reported in the scientific literature. Since modern PCR techniques is more sensitive than conventional methods, it can be anticipated that this microbe will be detected more frequently, even in newborns.Case presentation: The present report describes the clinical courses of two neonates contaminated with T. vaginalis documented by multiplex PCR. The pathogens were detected in newborns without obvious clinical suspicion of sexually transmitted infections.Conclusion: T.vaginalis can be transmitted from an infected mother to her child during vaginal delivery resulting either in transient colonization or in manifest disease. It is likely that in the future, when multiplex PCR becomes more widely apllied, sexually transmitted infections will be detected more frequently in neonates.","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data.

IF 5.4 2区医学

Infection Pub Date : 2025-03-22 DOI: 10.1007/s15010-025-02505-z

Myriam Drysdale, Rose Chang, Tracy Guo, Mei Sheng Duh, Jennifer Han, Helen Birch, Catherine Sharpe, Daisy Liu, Sarah Kalia, Melissa Van Dyke, Maral DerSarkissian, Iain A Gillespie

{"title":"Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data.","authors":"Myriam Drysdale, Rose Chang, Tracy Guo, Mei Sheng Duh, Jennifer Han, Helen Birch, Catherine Sharpe, Daisy Liu, Sarah Kalia, Melissa Van Dyke, Maral DerSarkissian, Iain A Gillespie","doi":"10.1007/s15010-025-02505-z","DOIUrl":"https://doi.org/10.1007/s15010-025-02505-z","url":null,"abstract":"Purpose: To assess the impact of early sotrovimab treatment versus no treatment on the risk of developing post-acute sequelae of COVID-19 (PASC; long COVID) in patients (age ≥ 12 years) with COVID-19 at high risk for progression to severe disease.Methods: Retrospective cohort study using the US National COVID Cohort Collaborative (N3C) data. Phase 1 identified and assessed multiple definitions of PASC; Phase 2 evaluated the effectiveness of sotrovimab for reducing the risk of PASC, utilizing definitions from Phase 1. Average treatment effect in the treated (ATT)-weighted Cox proportional hazards regression models were used to compare time to event for PASC between high-risk patients who received sotrovimab treatment between May 26, 2021 and April 5, 2022, and high-risk patients with COVID-19 diagnosed between May 26, 2021 and March 26, 2022 who did not receive any treatment for COVID-19 during the acute phase or any pre-exposure prophylaxis against SARS-CoV-2.Results: A total of 9,504 sotrovimab-treated and 619,668 untreated patients were included in the main analysis. Most baseline characteristics were balanced between the two cohorts after ATT weighting. The doubly robust ATT-weighted hazard ratio (95% confidence interval) was 0.92 (0.89-0.96) (p < 0.001), indicating that sotrovimab use was associated with a significantly lower risk of PASC. Results remained consistent in sensitivity analyses.Conclusion: In patients at high risk for severe COVID-19, the benefits of early sotrovimab treatment may extend beyond the acute phase of COVID-19 and contribute to the prevention of PASC symptoms.","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney involvement in leptospirosis: a systematic review and meta-analysis.

IF 5.4 2区医学

Infection Pub Date : 2025-03-20 DOI: 10.1007/s15010-025-02492-1

Astha Sethi, Tirlangi Praveen Kumar, Kutty Sharada Vinod, Carl Boodman, Rachana Bhat, Prithvishree Ravindra, Souvik Chaudhuri, Seema Shetty, V Shashidhar, Attur Ravindra Prabhu, Nitin Gupta

{"title":"Kidney involvement in leptospirosis: a systematic review and meta-analysis.","authors":"Astha Sethi, Tirlangi Praveen Kumar, Kutty Sharada Vinod, Carl Boodman, Rachana Bhat, Prithvishree Ravindra, Souvik Chaudhuri, Seema Shetty, V Shashidhar, Attur Ravindra Prabhu, Nitin Gupta","doi":"10.1007/s15010-025-02492-1","DOIUrl":"https://doi.org/10.1007/s15010-025-02492-1","url":null,"abstract":"Introduction: From a public health perspective, it is essential to understand the burden of kidney involvement in leptospirosis. We aimed to assess the frequency of acute kidney injury (AKI) and chronic kidney disease (CKD) in patients with leptospirosis.Methodology: This systematic review and meta-analysis included all articles up to 14.08.2024 from three databases (PubMed, Scopus, Web of Science) using search terms related to leptospirosis and kidney involvement. After de-duplication, two independent reviewers independently checked the articles in two phases (title-abstract and full-text), and a third reviewer adjudicated any conflicts. Patient demographics, diagnostic procedures, and details of kidney involvement were extracted from the included studies. Risk of bias analysis was done using the Joanna Briggs Institute critical appraisal tool. A random effects model estimated the pooled rates for AKI, oliguria, and the need for dialysis.Results: Of the 5913 retrieved articles, 48 met the eligibility criteria. The pooled incidence of AKI, reduced urine output, and dialysis requirement was 49.2% (95%CI: 38.2-60.2%, I2 of 99.4%), 31.5% (95%CI: 24.2-38.7%, I2-96.1%) and 14.4% (95%CI: 10.3-18.4%, I2-97%) respectively. The pooled mean serum creatinine and urea levels at admission were 3.6 mg/dl (95% CI: 2.9-4.2, I2-99.1%) and 131.8 mg/dl (95% CI: 98.7-164.9, I2-98.6%), respectively. In four studies, the incidence of new-onset CKD after leptospirosis infection varied from 13 to 62%.Conclusion: AKI reduced urine output and the requirement for dialysis are frequent complications in patients with leptospirosis. Increased resources for their management in endemic areas are essential to mitigate the burden.","PeriodicalId":13600,"journal":{"name":"Infection","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: A practice already in use: a snapshot survey on the use of doxycycline as a preventive strategy (Doxy-PEP and Doxy-PrEP) in the GBMSM population in Spain.

IF 5.4 2区医学

Infection Pub Date : 2025-03-19 DOI: 10.1007/s15010-025-02514-y

Sergio Villanueva Baselga, Ruben Mora, Luis Villegas

引用次数: 0

Infection最新文献